2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2639

Predicting Flare and Sustained Clinical Remission after Adalimumab Withdrawal Using the Multi-Biomarker Disease Activity (MBDA) Score
Abstract Number: 2640

Can GP88 (Progranulin) be Used to Predict the Efficacy of Infliximab?
Abstract Number: 2641

Safety of Synthetic and Biological Dmards: Slr Informing the Update of the EULAR Recommendations for the Management of RA
Abstract Number: 2643

Risk Factors of Pneumocystis Jiroveci Pneumonia (PJP) in Patients with RA and Sulfasalazine As a Possible Protective Agent
Abstract Number: 2644

Patient Survey Regarding Generic and Bio-Similar Drugs
Abstract Number: 2645

Treatments for Early Rheumatoid Arthritis (RA): A Systematic Review of Randomized Controlled Trials
Abstract Number: 2646

Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): A Systematic Review and Meta-Analysis
Abstract Number: 2647

Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)
Abstract Number: 2648

Predictive Role of Biomarkers for the Response to Biologic Therapy in Rheumatoid Arthritis. Old, New and How Future Looks like?
Abstract Number: 2649

Patient Preferences Regarding Rheumatoid Arthritis Therapies in Lebanon: Results from a National, Multicenter, Cross-Sectional Survey
Abstract Number: 2650

Prediction of Inhibition of Radiographic Progression By Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global, Phase 3 Trial
Abstract Number: 2651

Predictors of Inadequate Response and Rapid Radiographic Progression in Patients with Early Rheumatoid Arthritis Receiving Methotrexate: a Post Hoc Analysis of 2 Randomized, Controlled Trials of Adalimumab
Abstract Number: 2652

Rheumatoid Arthritis and Excess Mortality Associated with Treatments: a Systematic Review and Meta-Analysis
Abstract Number: 2653

Results of a Comprehensive Review of Pulmonary Function and Safety Data in a Phase IIb Clinical Program Testing Anti-GM-CSF Receptor Antagonist Mavrilimumab for Treatment of RA
Abstract Number: 2654

Association Between Rheumatoid Factor Positivity and Effects of Treatment with a First Biologic Agent in Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].